CorMedix Inc. (NYSEMKT:CRMD) will post its quarterly earnings results after the market closes on Wednesday, August 9th. Analysts expect CorMedix to post earnings of ($0.16) per share for the quarter.

Shares of CorMedix Inc. (NYSEMKT:CRMD) traded up 5.088% during midday trading on Monday, reaching $0.378. The company had a trading volume of 177,431 shares. The company’s market capitalization is $15.36 million. The company has a 50-day moving average price of $0.42 and a 200 day moving average price of $1.12. CorMedix Inc. has a one year low of $0.34 and a one year high of $3.26.

COPYRIGHT VIOLATION NOTICE: “CorMedix Inc. (NYSEMKT:CRMD) Set to Announce Earnings on Wednesday” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

A number of research firms recently weighed in on CRMD. Zacks Investment Research lowered CorMedix from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. FBR & Co reaffirmed a “buy” rating on shares of CorMedix in a research report on Monday, April 24th. Finally, Rodman & Renshaw reduced their price objective on CorMedix from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, May 5th.

In related news, CEO Khoso Baluch acquired 75,000 shares of CorMedix stock in a transaction that occurred on Wednesday, May 17th. The stock was bought at an average price of $0.48 per share, with a total value of $36,000.00. Following the transaction, the chief executive officer now directly owns 85,000 shares in the company, valued at $40,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 203,781 shares of company stock valued at $98,362.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Earnings History for CorMedix (NYSEMKT:CRMD)

Receive News & Ratings for CorMedix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix Inc. and related companies with's FREE daily email newsletter.